<DOC>
	<DOCNO>NCT00811070</DOCNO>
	<brief_summary>This two-part safety efficacy study SKI-606 subject Philadelphia chromosome positive leukemia ( CML ) . Part 1 dose-escalation study , escalate dose SKI-606 ( Bosutinib ) , 600 mg , studied subject imatinib resistant/refractory imatinib intolerant chronic phase CML . Part 2 evaluate safety efficacy maximum tolerate dose ( MTD ) SKI-606 ( Bosutinib ) identify Part 1 study .</brief_summary>
	<brief_title>Study Evaluating SKI-606 ( Bosutinib ) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>Cytogenetic Polymerase Chain Reaction base diagnosis Chronic phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia : ( Part 1 ) , phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia ( Part 2 ) , whose disease resistant/refractory fulldose imatinib ( 400 mg chronic phase subjects/600 mg advance leukemia subject ) , intolerant dose imatinib . Adequate duration prior imatinib therapy . No prior exposure Src , Abl , Src/Abl kinase inhibitor imatinib . Eastern Cooperative Oncology Group Performance Status 0 1 chronic phase subject , 0 , 1 2 Advanced Stage subject . At least 7 day since antiproliferative treatment ( include intrathecal chemotherapy ) first dose SKI606 , ( except hydroxyurea ) . Recovered National Cancer Institute grade 01 , baseline , toxicity prior antitumor treatment , alopecia thrombocytopenia due active prior treatment ( intolerant subject ) . At least 3 month post allogeneic stem cell transplantation first dose SKI606 . Able take daily oral capsule reliably . Absolute neutrophil count great 1,000/mL ( Part 1 ) Adequate hepatic , renal function . Documented normal INR oral anticoagulant therapy , , oral anticoagulant therapy consistent target INR le 3 . Age great 20 year less 75 year ( Part 1 ) , great 20 year ( Part 2 ) , include woman childbearing potential . Willingness male female subject , surgically sterile postmenopausal , must agree commit use reliable method birth control ( oral contraceptive , intrauterine device , barrier method use spermicide ) duration study 30 day last dose SKI606 . Subjects Philadelphia chromosome negative Chronic Myelogenous Leukemia . Overt leptomeningeal leukemia . Subjects must free CNS involvement accord symptom minimum 2 month first dose SKI606 . Subjects CNS symptom must diagnostic lumbar puncture prior study enrollment . Subjects extramedullary disease . Ongoing requirement warfarin oral anticoagulant therapy ( Part 1 ) . Ongoing requirement hydroxyurea ( Part 1 ) . Graft Versus Host Disease . a. previous Graft Versus Host Disease allow ( Part 1 ) . b. treat untreated Graft Versus Host Disease within 60 day first dose ( Part 2 ) . Major surgery within 14 day radiotherapy within 7 day first dose SKI606 ( recovery previous surgery complete day 1 ) . Ongoing clinical requirement administration strong inhibitor inducer CYP3A4 ( Part 1 ) . History clinically significant uncontrolled cardiac disease include : a. history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) b. diagnose suspected congenital acquire prolonged QT syndrome c. history prolong QTc d. unexplained syncope e. history active congestive heart failure f. myocardial infarction within 12 month . g. Uncontrolled angina hypertension within 3 month . Baseline QTcF great 0.45 sec ( average triplicate reading ) . Concomitant use need medication know prolong QT interval . Uncorrected hypomagnesemia hypokalemia due potential effect QT interval . Recent ( within 14 day first dose SKI606 ) ongoing clinically significant gastrointestinal disorder . Pregnant breastfeed woman . Evidence serious active infection , significant medical psychiatric illness .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>CML . Chronic myelocytic leukemia . Philadelphia Chromosome . Japanese . SKI-606 . Bosutinib . Imatinib resistant . Imatinib intolerant</keyword>
</DOC>